| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 100mg | |||
| 250mg | |||
| 500mg | |||
| Other Sizes |
| Targets |
Flu-IA targets juvenile hormone binding proteins and receptors. It binds to these proteins with high affinity, allowing for the study of juvenile hormone signaling in insects.
|
|---|---|
| ln Vitro |
CE-LIF was used to examine the 8 μM GSH sample solutions after they had been derivatized with 8, 80, 200, 400, 800, 1600, 2000, and 2500 μM 5-IAF, in that order. Using 400 and 800 μM 5-IAF, the maximum signal intensity was found [2].
In vitro, Flu-IA is used as a fluorescent probe to study juvenile hormone binding proteins. Its binding affinity and specificity are characterized in binding assays. |
| ln Vivo |
In vivo, Flu-IA is used to study juvenile hormone signaling in insects. It can be used to visualize the distribution of juvenile hormone binding proteins.
|
| Enzyme Assay |
In vitro binding assays for Flu-IA typically involve incubating the probe with insect tissue homogenates or purified proteins. Bound fluorescence is measured to determine binding affinity and specificity.
|
| Cell Assay |
Cell-based assays for Flu-IA involve treating insect cells with the probe and visualizing its localization using fluorescence microscopy. The probe's binding to juvenile hormone receptors is assessed.
|
| Animal Protocol |
In vivo insect studies for Flu-IA involve administering the probe to insects and visualizing its distribution. The probe's ability to label juvenile hormone binding proteins is assessed.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Flu-IA are not relevant for therapeutic applications. The compound is a fluorescent probe used in research.
|
| Toxicity/Toxicokinetics |
The toxicological profile of Flu-IA has not been extensively characterized. As a research compound, it should be handled with appropriate safety precautions.
|
| References |
|
| Additional Infomation |
Flu-IA is a fluorescent probe used to study juvenile hormone signaling in insects. It is not approved for therapeutic use. The compound is valuable for studying insect endocrinology.
|
| Molecular Formula |
C26H24IN3O4
|
|---|---|
| Molecular Weight |
569.39
|
| Exact Mass |
514.987
|
| CAS # |
63368-54-7
|
| PubChem CID |
123822
|
| Appearance |
Light yellow to orange solid powder
|
| Density |
1.95 g/cm3
|
| Boiling Point |
788.4ºC at 760 mmHg
|
| Melting Point |
265-267ºC (dec.)(lit.)
|
| Flash Point |
430.6ºC
|
| Index of Refraction |
1.781
|
| LogP |
4.415
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
30
|
| Complexity |
677
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
UATCLPJEZJKNHE-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C22H14INO6/c23-10-20(27)24-11-1-4-15-14(7-11)21(28)30-22(15)16-5-2-12(25)8-18(16)29-19-9-13(26)3-6-17(19)22/h1-9,25-26H,10H2,(H,24,27)
|
| Chemical Name |
N-(3',6'-dihydroxy-3-oxospiro[2-benzofuran-1,9'-xanthene]-5-yl)-2-iodoacetamide
|
| Synonyms |
FluIA; Flu IA; Flu-IA
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~97.04 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.85 mM) (saturation unknown) in 10% DMF 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (4.85 mM) in 10% DMF 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: 1.43 mg/mL (2.78 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. Solubility in Formulation 4: in 10% DMSO + 90% (20% SBE-β-CD in Saline) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7563 mL | 8.7813 mL | 17.5627 mL | |
| 5 mM | 0.3513 mL | 1.7563 mL | 3.5125 mL | |
| 10 mM | 0.1756 mL | 0.8781 mL | 1.7563 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
